Frontiers in Endocrinology (May 2023)

Patient decision aids for patients with differentiated thyroid carcinoma: development process and alpha and beta testing

  • Anna Koot,
  • Anna Koot,
  • Rosella Hermens,
  • Petronella Ottevanger,
  • Romana Netea-Maier,
  • Peep Stalmeier,
  • the COMBO study group,
  • Marieke Snel,
  • Noortje van der Kleij-Corssmit,
  • Johannes Bonenkamp,
  • Koen Dreijerink,
  • Evelien van Dam,
  • Grard Nieuwenhuijzen,
  • Mariel Keemers,
  • Lieke Welling,
  • Iris van der Ploeg,
  • Sanne Engelen,
  • Danielle Dercks,
  • Frans Geenen

DOI
https://doi.org/10.3389/fendo.2023.1162537
Journal volume & issue
Vol. 14

Abstract

Read online

BackgroundPatient decision aids (PtDAs) are structured clinical tools that facilitate shared decision-making. Two important treatment decisions for patients with differentiated thyroid cancer (DTC), which could benefit from PtDAs, are as follows (1): the extent of surgery decision in patients with low-risk DTC and (2) the decision to start or delay starting the treatment with tyrosine kinase inhibitors (TKIs) in patients with advanced tumors.Material and methodsPtDAs for these two decisions were developed using the International Patient Decision Aids Standards (IPDAS) quality criteria in an iterative process of prototype development via alpha and beta testing by patients and physicians. The information content of the PtDAs was based on the available literature, current guidelines, and patient’s needs, preferences, and values.ResultsThe web-based PtDAs underwent two rounds of alpha testing, revisions, and beta testing. The PtDAs have the same structure, consisting of six steps: a general introduction, information about the treatment options, comparing the treatment options, knowledge questions, a values clarification exercise, and saving the information. The alpha testing (n = 8 patients, n = 10 physicians) showed that the PtDAs were highly acceptable and usable for decision-making. Results of the beta testing in 20 patients showed that two patients did not use the PtDA; the other 18 patients found that the PtDAs were readable (n = 17) and helpful (n = 14) for decision-making. All patients recommend using the PtDAs.ConclusionsEvidence-based PtDAs were created for patients with DTC for two different treatment decisions. Our final version was judged to be clear, balanced, and helpful in decision-making.

Keywords